155 related articles for article (PubMed ID: 31155560)
1. A 3D-QSAR Analysis of CDK2 Inhibitors Using FMO Calculations and PLS Regression.
Yoshida T; Hirono S
Chem Pharm Bull (Tokyo); 2019; 67(6):546-555. PubMed ID: 31155560
[TBL] [Abstract][Full Text] [Related]
2. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6.
Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J
J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
[TBL] [Abstract][Full Text] [Related]
4. Structure-based and multiple potential three-dimensional quantitative structure-activity relationship (SB-MP-3D-QSAR) for inhibitor design.
Du QS; Gao J; Wei YT; Du LQ; Wang SQ; Huang RB
J Chem Inf Model; 2012 Apr; 52(4):996-1004. PubMed ID: 22480344
[TBL] [Abstract][Full Text] [Related]
5. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
Zhang G; Ren Y
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
[TBL] [Abstract][Full Text] [Related]
6. Molecular insights of benzodipyrazole as CDK2 inhibitors: combined molecular docking, molecular dynamics, and 3D QSAR studies.
Guttikonda V; Raavi D; Maadwar SK; Gade DR
J Recept Signal Transduct Res; 2015; 35(5):439-49. PubMed ID: 25902329
[TBL] [Abstract][Full Text] [Related]
7. How good are ensembles in improving QSAR models? The case with eCoRIA.
Khedkar VM; Joseph J; Pissurlenkar R; Saran A; Coutinho EC
J Biomol Struct Dyn; 2015; 33(4):749-69. PubMed ID: 24754910
[TBL] [Abstract][Full Text] [Related]
8. Prediction of cyclin-dependent kinase 2 inhibitor potency using the fragment molecular orbital method.
Mazanetz MP; Ichihara O; Law RJ; Whittaker M
J Cheminform; 2011 Jan; 3(1):2. PubMed ID: 21219630
[TBL] [Abstract][Full Text] [Related]
9. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
Chohan TA; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
[TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics and QM/MM-based 3D interaction analyses of cyclin-E inhibitors.
Pasha FA; Neaz MM
J Mol Model; 2013 Feb; 19(2):879-91. PubMed ID: 23086460
[TBL] [Abstract][Full Text] [Related]
11. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
[TBL] [Abstract][Full Text] [Related]
12. Assessment and acceleration of binding energy calculations for protein-ligand complexes by the fragment molecular orbital method.
Otsuka T; Okimoto N; Taiji M
J Comput Chem; 2015 Nov; 36(30):2209-18. PubMed ID: 26400829
[TBL] [Abstract][Full Text] [Related]
13. Molecular modeling studies of 4,5-dihydro-1H-pyrazolo[4,3-h] quinazoline derivatives as potent CDK2/Cyclin a inhibitors using 3D-QSAR and docking.
Ai Y; Wang ST; Sun PH; Song FJ
Int J Mol Sci; 2010 Sep; 11(10):3705-24. PubMed ID: 21152296
[TBL] [Abstract][Full Text] [Related]
14. Free-energy force-field three-dimensional quantitative structure-activity relationship analysis of a set of p38-mitogen activated protein kinase inhibitors.
Romeiro NC; Albuquerque MG; de Alencastro RB; Ravi M; Hopfinger AJ
J Mol Model; 2006 Sep; 12(6):855-68. PubMed ID: 16541250
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR CoMFA study on oxindole derivatives as cyclin dependent kinase 1 (CDK1) and cyclin dependent kinase 2 (CDK2) inhibitors.
Singh SK; Dessalew N; Bharatam PV
Med Chem; 2007 Jan; 3(1):75-84. PubMed ID: 17266627
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors.
Lan P; Chen WN; Xiao GK; Sun PH; Chen WM
Bioorg Med Chem Lett; 2010 Nov; 20(22):6764-72. PubMed ID: 20869873
[TBL] [Abstract][Full Text] [Related]
17. Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.
Yuan H; Liu H; Tai W; Wang F; Zhang Y; Yao S; Ran T; Lu S; Ke Z; Xiong X; Xu J; Chen Y; Lu T
SAR QSAR Environ Res; 2013 Oct; 24(10):795-817. PubMed ID: 23941641
[TBL] [Abstract][Full Text] [Related]
18. Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations.
Chen J; Pang L; Wang W; Wang L; Zhang JZH; Zhu T
J Biomol Struct Dyn; 2020 Mar; 38(4):985-996. PubMed ID: 30843759
[TBL] [Abstract][Full Text] [Related]
19. Computational approach for generating robust models for discovering novel molecules as Cyclin Dependent Kinase 4 inhibitors.
Divya V; Pushpa VL; Sarithamol S; Manoj KB
J Mol Graph Model; 2018 Jun; 82():48-58. PubMed ID: 29680736
[TBL] [Abstract][Full Text] [Related]
20. 4D-QSAR and MIA-QSAR study on the Bruton's tyrosine kinase (Btk) inhibitors.
Ma W; Wang Y; Chu D; Yan H
J Mol Graph Model; 2019 Nov; 92():357-362. PubMed ID: 31450065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
